RVTY

$85.94+0.18 (+0.21%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Revvity, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$85.94
Potential Downside
55%
Whystock Fair Value$38.70
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and in...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
41.72
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
3.93%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.40

Recent News

Barchart
Mar 20, 2026

Is Revvity Stock Underperforming the S&P 500?

Revvity has lagged the broader S&P 500 over the past year, though analysts maintain a cautiously positive outlook on its forward growth potential.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 19, 2026

Research Tools & Consumables Stocks Q4 Results: Benchmarking Revvity (NYSE:RVTY)

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Insider Monkey
Mar 16, 2026

Emerald Growth Equity Strategy Sold Revvity (RVTY) in Q4

Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q4 2025 investor letter for the “Growth Equity Strategy.” A copy of the letter is available to download here. In 2025, the strategy returned +3.1% (gross) and +3.0% (net), resulting in the year-to-date return of 16.7% (gross) and +16.0% (net). […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 9, 2026

How The Revvity (RVTY) Narrative Is Shifting With Higher Targets And Tempered Growth Assumptions

Revvity’s fair value estimate has been revised from US$114.63 to US$119.56, a modest uplift that puts fresh attention on where analysts think the stock should trade. That shift lines up with bullish commentary pointing to recovering end markets, early improvement in China and healthier survey data on procedures and CapEx, even as expectations for growth and margins are more restrained. As you read on, you will see how this evolving narrative might shape the way you track Revvity from...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 6, 2026

Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
RVTY (Revvity, Inc) Stock Analysis | Whystock